Similarly, bevacizumab, etanercept, and pegfilgrastim also showed a decreasing trend in average biologics prices by $17.7 (849.8%), $0.5 (16.4%), and $128.5 (271.8%), although these reductions were not statistically significant.
← all excerpts
Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
1
—
—